Belgium's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is expected to witness growth from $65 Mn in 2022 to $116 Mn in 2030 with a CAGR of 7.5% for the year 2022-2030 due to factors like rising cases of ADHD among the Belgian population and the improved health expenditure for greater access to ADHD medications. The Belgium ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the major players in the market include Celyad, Confo Therapeutics, and Advanz Pharmaceuticals.
The Belgium Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $65 Mn in 2022 and is projected to reach $116 Mn in 2030, exhibiting a CAGR of 7.5% during the forecast period. In order to cover higher utility bills, the hospital industry in Belgium will receive $85.43 Mn in the first half of 2023. One of the budgetary measures will release $106.79 Mn as structural cost compensation for conventional healthcare providers—those who adhere to the formal fees set by physicians and healthcare organizations in Belgium. $106.79 Mn will be made available from the health insurance budget, which was unanimously passed, for structural cost compensation for healthcare providers, but only for those who are contracted. The highest co-payment ceilings will also not be indexed. Additional funding for accessible dental care, improved eyewear coverage, and targeted initiatives to improve treatment and quality of life for cancer patients are also planned.
The neurological condition known as Attention Deficit Hyperactivity Disorder (ADHD) is frequently affected by genetics. It is marked by impulsivity, restlessness, or hyperactivity. In the setting of primary care, it is the neurodevelopmental disorder with a childhood onset that is most commonly encountered. Most often, symptoms appear before the age of seven. According to a study by the Belgian Health Care Knowledge Centre (KCE) that was released in 2022, children and adolescents in Belgium between the ages of 6 and 17 are thought to have an ADHD prevalence of about 5.5%. No matter the patient's age, the High Council for Health (SHC) in Belgium emphasizes that the first course of treatment should be psycho-educative therapy, which also involves the patient's family and community. Other approaches should only be contemplated when that fails. Methylphenidate, better known by its brand name Ritalin, is currently the only ADHD drug that is reimbursed in Belgium for patients under the age of 18. Adults are not at all reimbursed by typical medical insurance. Non-drug therapies are either not adequately accessible in Belgium or are too expensive for many families to afford due to cost-reimbursement policies.
Market Growth Drivers
As the prevalence of ADHD rises and more people in Belgium are given the diagnosis, there is increasing demand for ADHD treatments like medication and psychotherapy. To more accurately identify and treat ADHD, breakthroughs in technology are being developed. As healthcare expenditure in Belgium rises, more funds are being directed toward ADHD treatment. This is anticipated to drive the Belgium ADHD therapeutics market's expansion.
Market Restraints
Financial hardships or resource limitations may make it more challenging for patients to receive treatment for ADHD. This may restrict the Belgium ADHD therapeutics market expansion. Some patients may experience negative side effects from their ADHD therapies, which may cause them to discontinue taking it or reduce their desire to take it. This might slow the Belgium ADHD therapeutics market's expansion.
Key Players
The Federal Agency for Medicines and Health Products, formerly the Directorate-General for Medicinal Products of the FPS Public Health (Agence Federerale des Medicaments et des Produits de Sante, FAMHP), was established in January 2007 and serves as Belgium's official agency for licensing pharmaceuticals and health products. The agency's goal is to guarantee the efficacy, safety, and quality of drugs and other medical supplies both during the clinical research process and once they hit the market. Moreover, it is in charge of approving the initial national marketing application for a medicinal product in accordance with the national, decentralized, and mutual acknowledgment procedures outlined in the Royal Decree of December 12, 2006. No drug may be marketed in Belgium without licensing or marketing authorization. On the basis of the applicant's scientific data, the experts chosen by the various authorities assess the drug's quality, safety, and effectiveness. They depend on European-level scientific standards for this assessment. Only products with clear evidence of their quality, safety, and efficacy are authorized for marketing as drugs. The same scientific criteria for quality, safety, and effectiveness must be met by all medications approved for marketing, whether they are trademarked or generic.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug Type (Revenue, USD Billion):
By Age Group (Revenue, USD Billion):
By Distribution Channel (Revenue, USD Billion):
By Psychotherapy (Revenue, USD Billion):
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?